Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

By Siddharth Singh, A. Allen, Zhen Wang, L. Prokop, M. H. Murad, R. Loomba. Clinical Gastroenterology and Hepatology, 2015

1,579 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Mechanisms and disease consequences of nonalcoholic fatty liver disease (2021, background): “It is estimated that only 20% of individuals with NAFLD have NASH, and 20% of these individuals may progress to cirrhosis over 3–4 decades (Singh et al., 2015).”
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. (2015, background): “6 years, which is in agreement with previous studies [17–26].”
Non-alcoholic fatty liver disease - A global public health perspective. (2019, background): “8 years.(55,56) These rates of progression or regression can be influenced by a number of genetic or environmental factors.”
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease (2018, background): “However, progression to fibrosis also occurs in patients with steatosis alone [7], although rates of progression and overall mortality rates are increased in NASH [1, 8].”
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease (2020, background): “18) fibrosis stage per year [262], the following schedule can be proposed as a general guidance (Fig.”